Trial
NCT03630120
Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Collaborators
—
Condition
Thyroid Cancer
Intervention
Lenvatinib
Why stopped
Lack of efficacy
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-07-14